leisure time -WSS

leisure time

author：knowledge 2025-09-30 22:41:18 - browse：14457

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： New case study details death in closely watched Alzhiemer's trial

WSS

How dance can help health care workers heal from trauma

4th of July breaks record for highest global temperature ever measured

New case study details death in closely watched Alzhiemer's trial

Did the public have the right to know Arthur Ashe had AIDS?

Can food be medicine? And other questions about a new push

Resistance to cancer drugs: A new genetic explanation

hotspot

leisure time

entertainment

Wildfire smoke exposes gaps in outdoor worker protections

Ebola public health emergency is over, WHO declares

Medical records are filled with copy

Celebrate National Dole Whip Day for 3 days this week at Disney

New air purifier tech could be key to improving indoor air quality

Norman Reedus' Daryl Dixon

Tori Bowie and the unacceptable rates of Black maternal death

Doctor appointment wait times are getting worse

BioMarin wins approval for gene therapy to treat hemophilia A

Medical experts are missing from AI regulatory conversations

knowledge

Ebola public health emergency is over, WHO declares

Resistance to cancer drugs: A new genetic explanation

Couple fighting to bring baby home from Mexico are finally reunited

Celebrate National Dole Whip Day for 3 days this week at Disney

DOJ, FTC to increase scrutiny of all types of health care mergers

India sets sights on home

hotspot

focus

hotspot

leisure time